Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals

Journal of Human Hypertension

Volumn 23, Issue 12, 2009, Pages 801-807

  Solini, A ^a   Santini, E ^a   Passaro, A ^b   Madec, S ^a   Ferrannini, E ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; GELATINASE A; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; PADGEM PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MONOCYTE; NORMAL HUMAN; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; FAMILY HEALTH; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; P-SELECTIN; PREVALENCE; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 70749158585     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.26     Document Type: Article

References (39)

1. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2007; 49: 1740-1749.
2. Romero JR. Prevention of ischemic stroke: Overview of traditional risk factors. Curr Drug Targets 2007; 8: 794-801.
3. Neutel JM. Why lowering blood pressure is not enough: The hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis 2000; 2: 370-374.
4. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.
5. Helderman F, Segers D, de Crom R, Hierck BP, Poelmann RE, Evans PC et al. Effect of shear stress on vascular inflammation and plaque development. Curr Opin Lipidol 2007; 18: 527-533.
6. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22: 545-551.
7. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-124.
8. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 2000; 75: 43-47.
9. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764-769.
10. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101.e1-1101.e8.
11. Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, Todor A et al. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol 2006; 290: H2522-H2527.
12. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179.
13. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: A substudy of the Anglo-Scandinavian cardiac outcomes trial. J Intern Med 2007; 261: 384-391.
14. Chironi G, Dosquet C, Del-Pino M, Denarie N, Megnien JL, Drouet L et al. Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. Am J Hypertens 2006; 19: 1025-1031.
15. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88: 3005-3010.
16. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321-327.
17. Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N et al. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond) 2008; 114: 449-455.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC VII Report. JAMA 2003; 289: 2560-2572.
19. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques: Coexpression with intercellular adhesion molecule-1. Am J Pathol 1994; 144: 952-961.
20. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
21. Yasmin, Wallace S, McEniery CM, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372-378.
22. Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006; 26: 1799-1805.
23. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17: 770-774.
24. Nanni L, Romualdi C, Maseri A, Lanfranchi G. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. Mol Cell Cardiol 2006; 41: 934-948.
25. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97 175-180.
26. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875-880.
27. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-1126.
28. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674-682.
29. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 2005; 183: 308-315.
30. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res 2004; 12: 962-971.
31. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A et al. Interleukin 6-174 G/C promoter polymorphism and risk of coronary heart disease: Results from the Rotterdam study and a metaanalysis. Arterioscler Thromb Vasc Biol 2006; 26: 212-217.
32. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: Tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15: 1914-1920.
33. Pankow JS, Jacobs DR Jr, Steinberger J, Moran A, Sinaiko AR. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 2004; 27: 775-780.
34. Ansell BJ. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007; 100: 3-9.
35. Gomez-Rosso L, Benitez MB, Fornari MC, Berardi V, Lynch S, Schreier L et al. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Atherosclerosis 2008; 199: 415-423.
36. Li LJ, Geng SR, Yu CM. Endothelial dysfunction in normotensive Chinese with a family history of essential hypertension. Clin Exp Hypertens 2005; 27: 1-8.
37. Nakamura G, Kugiyama K. Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep 2006; 8: 107-110.
38. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007; 56: 799-805.
39. Kralisch S, Bluher M, Tonjes A, Lossner U, Pashke R, Stumvoll M et al. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol 2007; 156: 257-261.